The question for long-term investors is whether Intellia Therapeutics' shares look attractive under each scenario -- whether or not nex-z is responsible. Let's start with the more optimistic one. If the answer is "no" for the more bullish case, it will also be "no" for any other. True, nex-z could have a vast addressable market. The hereditary version of transthyretin amyloidosis affects only about 50,000 people, but the wild type (that tends to come with age) has a larger estimated patient population of 20 ...